A xenograft model showed that, among sarcomas, the only xenograft mice with significantly improved survival upon treatment with an inhibitory anti-AXL antibody conjugate were MFS/UPS cases.6 Several AXL-targeted therapeutics are in early clinical trials. Here, AXL is linked to Marfan syndrome.